Overview of Declofenac

Property	Description
Active Ingredient	Diclofenac
Pharmacological Class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Chemical Class	Phenylacetic acid derivative
Origin	Synthetic
General Purpose	Symptomatic relief of pain and inflammation

Declofenac is a pharmaceutical preparation whose primary component is the active ingredient diclofenac, which is a synthetic organic compound manufactured to treat pain and inflammation. This medicine is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and belongs chemically to the phenylacetic acid derivative class, distinguishing it from other common pain relievers. Its core function is to act as a non-narcotic analgesic, providing relief from discomfort without possessing the properties of opioid substances.

What Type of Medicine is Declofenac?

Declofenac is an NSAID used for its powerful anti-inflammatory, analgesic, and antipyretic properties, making it a foundational drug for reducing swelling, pain, and fever.

The active substance, diclofenac, works by temporarily interrupting the body's processes that lead to inflammation. It is considered an essential agent for its action as an anti-inflammatory and pain-relieving treatment, and is recognized as a fundamental option for addressing inflammatory pain. Unlike steroid-based treatments, this drug achieves its effects by targeting the enzymes responsible for creating prostaglandins, which are the chemical messengers that initiate pain and swelling at a cellular level. This mechanism is known for reducing swelling in conditions associated with inflammation.

What is Declofenac Made Of and What Forms Does it Come In?

The primary active ingredient in Declofenac is diclofenac, most commonly supplied as a salt, such as diclofenac sodium or diclofenac potassium, and is available in many physical forms.

As a single-ingredient product, the entire therapeutic effect of the medicine is derived from the diclofenac compound. This key substance is incorporated into a variety of dosage forms tailored for different administration routes. The medicine is available across numerous formulations, including topical gels and oral tablets, providing a variety of delivery options for patients. The differing salt forms, such as diclofenac sodium and diclofenac potassium, impact the medicine's rate of absorption but maintain the consistent core pharmacological effect. Common forms include solid oral preparations like tablets and capsules, as well as topical preparations like gels or solutions that rely on a polymeric or aqueous base for localized delivery.

Therapeutic Uses of Declofenac

What Declofenac Treats: Main Uses and Benefits

Declofenac, which contains the active ingredient diclofenac, provides symptomatic support across therapeutic domains marked by physical discomfort, inflammatory or irritative states, or systemic imbalance. This medication is commonly used in areas where short-term or long-term symptomatic support is appropriate, contributing to easing the overall symptom load and helping improve day-to-day comfort. It generally helps address symptoms that create noticeable physiological strain and symptoms that interfere with daily functioning.

Easing Chronic Joint Pain and Stiffness

This medication may assist with managing the persistent discomfort of chronic inflammatory and degenerative joint diseases, including rheumatoid arthritis and osteoarthritis. It is used for managing symptom clusters such as sustained joint pain, noticeable morning stiffness, and joint swelling, supporting general well-being during symptomatic phases. It is also applied in addressing conditions involving episodic or fluctuating manifestations, such as the pain and cramping of primary dysmenorrhea or the symptoms related to physical discomfort of acute migraine attacks.

Quick Fact: Relief for Inflammation and Pain

Declofenac is relevant when supportive symptom management is appropriate, offering relief for the persistent joint pain and swelling of chronic disorders, and symptoms following trauma or surgical procedures. It supports patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Diclofenac

This section summarizes the official eligibility and non-eligibility information for diclofenac, strictly based on regulatory documents.

Populations for Whom Use is Contraindicated

Diclofenac must not be used by patients with:

A known hypersensitivity to diclofenac or any components of the drug.
A history of asthma, hives, or other allergic-type reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
Use in the setting of coronary artery bypass graft (CABG) surgery.
Active stomach or duodenal ulceration or gastrointestinal bleeding.
Established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
Congestive heart failure classified as New York Heart Association (NYHA) II-IV or severe, uncontrolled heart failure.
Pregnancy, starting at 30 weeks gestation (due to risk of premature closure of the fetal ductus arteriosus).

Use Restrictions and Special Considerations

Advanced Renal or Severe Heart Failure: Use should be avoided unless the expected benefits significantly outweigh the risk of worsening the condition.
Age: Safety and efficacy are not established for children under 12 years of age (depending on formulation). Elderly patients are at greater risk for serious gastrointestinal and renal events.
Cardiovascular Risk: Treatment for patients with significant cardiovascular risk factors (e.g., hypertension) should be undertaken only after careful consideration, using the lowest effective dose for the shortest possible duration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for diclofenac is defined by risks of pharmacodynamic reinforcement and pharmacokinetic clearance modification, as detailed in official regulatory documents.

Interaction Type	Interacting Substances/Classes
Formal Contraindications	CABG surgery (perioperative pain), Other NSAIDs (including aspirin in analgesic doses), Aspirin-sensitive asthma history.
Increased Bleeding Risk	Anticoagulants (e.g., Warfarin), Antiplatelet agents, and SSRIs/SNRIs due to synergistic effects on hemostasis.
Exposure Modification	Lithium and Methotrexate: Diclofenac reduces the renal clearance of these drugs, leading to elevated plasma levels and potential toxicity. CYP2C9 Inhibitors (e.g., Voriconazole) increase diclofenac exposure.
Therapeutic Antagonism	Diuretics (e.g., Furosemide, Thiazides) and Antihypertensives (e.g., ACE-Inhibitors/ARBs) whose blood pressure or natriuretic effects may be diminished.
Other Restrictions	Alcohol use increases the risk of serious gastrointestinal events. Mifepristone use requires an 8-to-12-day separation window to avoid reduced effectiveness.

Co-administration with blood pressure medications in the elderly, volume-depleted, or renally compromised populations increases the official risk of renal impairment. These classifications establish constraints required for safe co-administration, specifically when concurrent use is documented to alter drug exposure or intended therapeutic outcomes.

Mechanism of Action

Core Mechanism: COX Enzyme Inhibition and Prostaglandin Synthesis

The primary mechanism of diclofenac involves the reversible inhibition of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. By blocking these enzymes, the drug prevents the conversion of arachidonic acid into pro-inflammatory mediators, chiefly prostaglandin E2 ( PGE2). This action restricts the formation of chemical mediators associated with physiological responses.

Physiological Cascade: Dampening Nociception and Thermal Regulation

The resulting decrease in PGE2 concentration leads to two key physiological consequences. Peripherally, it dampens the sensitization of nociceptors (pain-sensing nerves), limiting the transmission of nociceptive signals. Centrally, the mechanism suppresses the pyrogenic action of PGE2 in the hypothalamus, which leads to the reversal of the elevated thermal set-point. These actions affect the system's inflammatory and thermal responses, resulting in a change in the acute physiological response.

Dosage and Administration Information

The administration of Declofenac follows established protocols across several approved delivery routes and formulations. The medicine is available for oral intake as immediate-release, delayed-release, and extended-release tablets, and as a powder for oral solution. It is also approved for topical, rectal (suppositories), intravenous (IV), and intramuscular (IM) administration.

Usage Principles and Dosing

The fundamental usage principle requires prescribing the lowest effective dose for the shortest duration possible to address the usage goal. Dosing is customized based on the condition being addressed, ranging from short-term intermittent use for acute symptoms to long-term divided doses for chronic conditions.

Indication Type	Daily Dose Range (Oral)	Max Daily Intake	Frequency Pattern
Chronic Conditions (e.g., OA)	100 mg to 150 mg	150 mg	Divided doses or once daily (ER)
Chronic Conditions (e.g., RA)	150 mg to 225 mg	225 mg	Divided doses (b.i.d. or t.i.d.)

Administration Requirements and Constraints

Specific procedural constraints must be adhered to based on the formulation. Delayed-release and extended-release tablets must be swallowed whole and cannot be crushed, chewed, or divided. For the oral solution, the dose must be mixed with 1 to 2 ounces of water only and consumed immediately, preferably on an empty stomach. The injectable forms are generally designated for short-term use, typically restricted to a period of not more than two days. Population-specific usage guidance emphasizes administering the lowest effective dose to older adults or patients with low body weight.

Recent Clinical Evidence

Research evidence / Overview of studies for Diclofenac

The information below provides a high-level summary of the types of official research that have been conducted for diclofenac, outlining the studies' focus areas, the patient populations examined, and the primary outcomes monitored. This overview is based solely on authoritative regulatory and scientific literature.

Evidence for Chronic Joint Pain and Inflammation

The research base for the study of chronic joint pain and related inflammation, such as that associated with osteoarthritis (OA) and rheumatoid arthritis (RA), relies on numerous controlled studies. Randomized Controlled Trials (RCTs) and comprehensive systematic reviews were used in research exploring how symptoms change over time for these conditions. Studies monitored outcomes related to physical discomfort, such as patient-reported pain intensity scores, and outcomes reflecting daily functioning or activity level.

Studies on Systemic vs. Localized Treatment for Joint Pain

Studies explored and monitored both systemic (oral) and topical (localized) approaches. Topical research has explored its application in studies examining patient-reported experiences for localized joint pain, such as that in the knee or hand. Studies monitored reports of localized pain and reports of regional physical function. Evidence quality varies across studies, and follow-up durations were often limited in controlled topical trials, meaning data for certain groups, or long-term functional experience, remain less characterized.

Evidence for Acute Pain Relief and Short-Term Use

Diclofenac was studied for its use in acute pain and inflammation, including post-operative pain, acute migraine attacks, and primary dysmenorrhea. The evidence for acute use is concentrated in highly controlled, short-term RCTs. Research examined outcomes describing episodic or acute changes and monitored symptom patterns in settings related to phases of heightened symptom activity. Studies explored how quickly patients reported reports of pain intensity. However, this research is concentrated on immediate, short-term outcomes, and there is limited information regarding the implications of repeated use over extended periods.

Evidence Gaps and Areas of Research Uncertainty

Key limitations in the current evidence base include that follow-up durations were limited across many pivotal trials. Evidence quality varies across studies, and findings were mixed in some areas. Comparative evidence is lacking in some areas against every other available treatment. The research is consistently limited to outcomes related to physical discomfort and does not explore outcomes related to disease modification. Furthermore, data for certain subgroups (e.g., specific comorbidities) remain insufficient, and clinical trial data for groups outside of the studied adult populations are still emerging.

Key Studies & References Safety review of diclofenac - Therapeutic Goods Administration (TGA)

Frequently Asked Questions (FAQ)

Common questions about Declofenac (FAQ)

Q: Can I drink alcohol while taking diclofenac?

Official product labeling states that consuming alcohol while taking diclofenac significantly increases the risk of serious gastrointestinal events. These serious events include bleeding, ulceration, and perforation of the stomach or intestines. Regulatory documents indicate that combining alcohol with diclofenac increases the risk and caution against its use.

Q: Which other medications should not be taken with diclofenac?

Official product information states that diclofenac is formally contraindicated in combination with certain other substances. Specifically, it is contraindicated for use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including taking aspirin at analgesic doses. Diclofenac is also strictly contraindicated for treating pain following coronary artery bypass graft (CABG) surgery.

Q: If I miss a dose of diclofenac, what should I do?

Official patient information often describes the standard procedure for a missed dose: generally, a single missed dose is taken when remembered, unless the next dose is due soon. The guidance typically states that a double dose should not be taken to compensate for a missed dose. This information is provided to maintain a consistent dosing schedule.

Q: Is diclofenac addictive or a controlled substance?

Diclofenac is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is described as a non-narcotic analgesic, meaning it is a pain reliever that is not an opioid. According to regulatory bodies, diclofenac is not designated as a controlled substance and is not associated with addiction or dependence.

Q: Can diclofenac be used to treat a fever?

Official information regarding diclofenac's pharmacological properties confirms that it possesses antipyretic properties. This means the drug contains the inherent pharmacological property of reducing fever, in addition to its anti-inflammatory and pain-relieving effects.

Q: Does diclofenac come in a liquid form for children?

While diclofenac is available in various forms, including oral solutions, official product information indicates that safety and efficacy are not established for children under a certain age (often 12 years) for many formulations. Therefore, use is restricted based on age for specific products, and the age limit varies by formulation.

Q: What is the proper way to dispose of unused diclofenac?

According to official disposal guidelines, utilizing a drug take-back program is the preferred method for disposing of unused or expired diclofenac. When a take-back program is unavailable, official guidelines recommend certain steps, such as mixing the medicine with an undesirable substance (like coffee grounds), placing it in a sealed container, and discarding it in the trash, consistent with proper pharmaceutical waste disposal practices. Diclofenac should generally not be flushed.

How should Declofenac be stored and disposed of?

How to Store and Dispose of Diclofenac

Diclofenac (Declofenac) tablets must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). The medication must be kept from freezing and protected from moisture and excessive heat.

Protection and Safety

Storage requires keeping the product in its original, closed container to maintain stability. For safety, diclofenac must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired diclofenac must be disposed of according to local pharmaceutical waste regulations and should generally not be flushed down the toilet or placed in household trash. Drug take-back programs are the preferred method for discarding the product.

Entity	Official Regulatory Statement/Documentation
Documented Overdose Presentations	Symptoms include nausea, vomiting, stomach pain, diarrhea, dizziness, headache, and tinnitus (ringing in the ears). More severe presentations include little or no urine output and breathing difficulties.
Serious/Life-Threatening Outcomes	The regulatory profile notes potential for gastrointestinal hemorrhage, acute renal injury, and serious CNS events such as seizures and coma following a very large overdose.
Emergency-Response Statements	Immediate emergency medical attention is required for any suspected overdose. Contact emergency medical services or a poison control center without delay, as explicitly mandated in official guidance.
Official Management	No specific antidote is documented in the regulatory labeling. Treatment is symptomatic and supportive, which may involve the administration of activated charcoal and hospital observation.
Population-Specific Overdose Notes	Elderly patients are documented as being at greater risk for serious gastrointestinal adverse events. Individuals with pre-existing asthma may face a heightened risk of wheezing or trouble breathing.

Declofenac